Pacritinib: a new agent for the management of myelofibrosis?

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

(2015) R. S. Komrokji et al.   BLOOD

Effect of Mutation Order on Myeloproliferative Neoplasms

(2015) Christina A. Ortmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

How I treat polycythemia vera

(2014) A. M. Vannucchi   BLOOD

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

(2014) R. Norfo et al.   BLOOD

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

(2014) John T. Reilly et al.   BRITISH JOURNAL OF HAEMATOLOGY

Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation

(2014) Yan Beauverd et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

(2014) A Tefferi et al.   LEUKEMIA

Disseminated tuberculosis associated with ruxolitinib

(2014) R K Hopman et al.   LEUKEMIA

Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis

(2013) Heinz Gisslinger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy

(2013) Claire N. Harrison et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups

(2013) Jean-Christophe Ianotto et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome

(2013) Garrett W. Rhyasen et al.   CANCER CELL

An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor

(2013) Nicholas G. Wysham et al.   CHEST

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

(2013) S. Verstovsek et al.   HAEMATOLOGICA

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

(2013) Moshe Talpaz et al.   Journal of Hematology & Oncology

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis

(2013) G Caocci et al.   LEUKEMIA

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

(2013) A Pardanani et al.   LEUKEMIA

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival

(2012) T. L. Lasho et al.   BLOOD

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012

(2012) Donal P. McLornan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

(2012) Robyn M. Emanuel et al.   JOURNAL OF CLINICAL ONCOLOGY

Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

(2012) Priya Koppikar et al.   NATURE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor

(2012) Michael R. Marit et al.   PLoS One

Recombinant interferon-  may retard progression of early primary myelofibrosis: a preliminary report

(2011) R. T. Silver et al.   BLOOD

JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation

(2011) Fan Liu et al.   CANCER CELL

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

(2011) A V Purandare et al.   LEUKEMIA

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

(2011) A Deshpande et al.   LEUKEMIA

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

(2011) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

(2011) Y Nakaya et al.   Blood Cancer Journal

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients

(2010) Alejandra Martínez-Trillos et al.   ANNALS OF HEMATOLOGY

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells

(2010) A Pellagatti et al.   LEUKEMIA

TLR8-dependent TNF-  overexpression in Fanconi anemia group C cells

(2009) S. M. Vanderwerf et al.   BLOOD

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD